Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
It’s an AB-rated generic therapeutic version of Durezol
OptumRx to make Pear’s three commercial Prescription Digital Therapeutics accessible to patients with Optum formulary access.
QIAreach SARS-CoV-2 antigen test, developed in collaboration with Ellume, is easy to use and provides accurate and objective results in 2 to 15 minutes
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Nexviazyme specifically targets the M6P receptor, the key pathway for enzyme replacement therapy, to effectively clear glycogen build-up in muscle cells
It had an estimated market size of US $ 32 million as of June 2021
Ultreon 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using AI -
The group now has 320 approvals and has so far filed over 400 ANDAs
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
Subscribe To Our Newsletter & Stay Updated
